导语： 在阿尔茨海默病治疗遭遇瓶颈的当下，一款已上市的带状疱疹疫苗正引发科学界的新期待。英国制药巨头葛兰素史克（GSK）宣布与英国痴呆研究所（UK DRI）合作，利用 NHS 接种政策调整形成的 “自然实验”，研究其明星疫苗 Shingrix ...

The British pharmaceutical giant is working with the U.K. Dementia Research Institute to exploit a “natural randomization” ...

The study will analyse electronic health records of 65- and 66-year olds from the UK’s National Health Service (NHS).

智通财经APP获悉，葛兰素史克(GSK.US)正在英国对一大群老年人进行研究，以确定其畅销的带状疱疹疫苗Shingrix是否能降低患痴呆症的风险。这可能为扩大该疫苗的适应症打开大门。据悉，该研究从2023年开始，为期四年，面向140万65岁至66岁的 ...

Prominent outside scientists who help the NIH evaluate its internal research programs are being abruptly removed ...

GSK said on Tuesday that it is studying a group of more than a million older adults in the UK to examine whether its ...

After multiple studies have suggested a link between its shingles vaccine and dementia prevention, GSK is taking advantage of ...

GSK partners with UK research groups to study if Shingrix shingles vaccine reduces dementia risk, analyzing NHS data from ...

The research collaboration, which will take four years to complete, will use population-level electronic health data from the NHS to assess the impact of GSK’s recombinant zoster vaccine Shingrix on ...

GSK Plc is studying a large group of elderly adults in the UK to determine if its blockbuster shingles vaccine reduces the risk of dementia, potentially opening the door to an expanded label for the ...

To test it prospectively, GSK will work with the UK Dementia Research Institute (UK DRI) and Health Data Research UK (HDR UK) ...

GSK, led by boss Emma Walmsley (pictured), is using the data of 1.4m adults aged 65 and 66 to examine the impact of its ...